Market Research Logo

Nanomedicine Market Analysis By Services (Therapeutics, Regenerative Medicine, Vaccines, In-vitro & In-vivo Diagnostics), By Application, (Clinical Oncology, Infectious diseases, Clinical Cardiology, Orthopedics, Neurology, Ophthalmology, Pneumology, Urol

Nanomedicine Market Analysis By Services (Therapeutics, Regenerative Medicine, Vaccines, In-vitro & In-vivo Diagnostics), By Application, (Clinical Oncology, Infectious diseases, Clinical Cardiology, Orthopedics, Neurology, Ophthalmology, Pneumology, Urology, Immunology, Genetics, Obstetrics, Dermatology, Dentistry, Dermatology) And Segment Forecasts to 2024

Global nanomedicine market is anticipated to reach USD 344.0 billion by 2024, according to a new report by Grand View Research, Inc. Development of novel nanotechnology-based drugs and therapies is driven by the need to develop therapies that have fewer side effects and are more cost-effective than conventional methods, in particular for cancer treatment.

Application of nanotechnology-based contrast reagents for diagnosis and monitoring of the effects of drugs is faster than most other methods and this benefit is quite essential for the attributed growth of the market in the coming years. Additionally, demand for biodegradable implants with longer half-lives that enable tissue restoration and enhance reparative therapy, are also anticipated to influence demand.

However, in contrary to the number of potential applications of nanotechnology, the entire process of lab-to-market approval is a tedious and expensive process with stringent regulatory evaluation, as a result of which investors do still remain a bit reluctant for investments in the field.

Further key findings from the report suggest:

Therapeutics accounted for the largest share of market revenue in 2015 as a result of the presence of nanoemulsions, nanoformulations, or nanodevices that possess the ability to cross biological barriers. Moreover, presence of drugs such as Doxil, Abraxane, and Emend is attributive for higher revenue generation.

In-vitro diagnostics is expected to witness lucrative progress as a result of R&D carried out for introduction of nano-enabled biomarkers, vectors and contrast agents with high-specificity and sensitivity. Furthermore, demand for biosensor surfaces that are nanostructured and tailored to work in-vivo environment is expected to further support the projected growth.

As per the WHO factsheet, cancer is found to be one of the major causes of morbidity and mortality worldwide, with approximately 8.2 million cancer-related deaths and 14 million new cases in 2012. Thus, demand for nanomedicine in order to curb such high incidence rate is expected to boost market progress during the forecast period.

Solutions such as nanoformulations with triggered release for tailor-made pharmacokinetic nanoparticles for local control of tumor in combination with radiotherapy, and functionalized nanoparticles for targeted in-vivo activation of stem cell production are factors anticipated to drive R&D, consequently resulting in revenue generation over the coming years.

Clinical cardiology is expected to witness fastest growth through to 2024 owing to development in nano-functionalization and modification of surfaces for increased biocompatibility of implants in treatment of late thrombosis.

North America led the industry in 2015, accounting for over 40% of revenue generated. Due to a number of key participants operating in this region which are involved in collaborative activities and research for incorporation of nanotechnology in conventional therapies is prenominal for this major share of North America in terms of revenue.

Moreover, an abundance of research publications and patent filings from European region with a share of about 25% in nanomedicine-related publications is supportive for considerable revenue generation expected from European economies as well.

Asia Pacific is projected to witness rapid growth over the foreseeable future as a number of government and regulatory authorities in the region have implemented initiatives to encourage R&D collaborations between regional biotech and international pharmaceutical companies. Growing investment interest by the western large pharmaceuticals in some of the key countries of the region coupled with ongoing government initiatives are factors expected to drive growth of the region.

Some key players operating in this industry include St. Jude Medical, Celgene Corporation, Bind Therapeutics Inc., Abraxis Inc., Ablynx NV, Bio-Gate AG, Nanotherapeutics Inc., Nanoviricides Inc., Arrowhead Research Inc., Pfizer, and Merck.

Biopharmaceutical and medical devices companies are engaged actively in the development of novel products as demonstrated by the rise in the number of international partnerships between leading enterprises and nanomedicine startups. For instance, in November 2015, Ablynx and Novo Nordisk signed a global collaboration and licensing agreement for development and discovery of innovative drugs with multi-specific nanobodies. This strategic partnership is anticipated to rise the net annual sales of the products of both entities thereby uplifting market growth in the process


Chapter 1 Research Methodology
1.1 Information Procurement
1.2 Data Analysis
Chapter 2 Executive Summary
Chapter 3 Market Snapshot
Chapter 4 Market Variables, Trends & Scope
4.1 Market segmentation&scope
4.1.1 Market driver analysis
4.1.1.1 Rising level of government participation in R&D funding
4.1.1.2 Introduction of technological advancements in disgnostic procedures
4.1.1.3 Rising usage of nanomedicine in drug delivery technology
4.1.1.4 Increasing knowledge of molecular processes linked to diseases
4.1.2 Market restraint analysis
4.1.2.1 Side effects associated with intake of nanoparticles and lower adoption rate by patients
4.1.2.2 Hesitant uptake by medical and pharmaceutical industry
4.2 Penetration & growth prospect mapping for products, 2015
4.3 Penetration & growth prospect mapping for applications, 2015
4.4 Nanomedicine - SWOT analysis, by factor (political & legal, economic and technological)
4.5 Industry analysis - Porter’s
4.6 Pipeline analysis, 2015
Chapter 5 Market Categorization 1: Product Estimates & Trend Analysis
5.1 Nanomedicine market: product movement analysis
5.2 Therapeutics
5.2.1 Global therapeutics market, 2013 - 2024 (USD Billion)
5.3 Regenerative medicine
5.3.1 Global regenerative medicine market, 2013 - 2024 (USD Billion)
5.4 In-vitro diagnostics
5.4.1 Global in-vitro diagnostics market, 2013 - 2024 (USD Billion)
5.5 In-vivo diagnostics
5.5.1 Global in-vivo diagnostics market, 2013 - 2024 (USD Billion)
5.6 Vaccines
5.6.1 Global vaccines market, 2013 - 2024 (USD Billion)
Chapter 6 Market Categorization 2: Application Estimates & Trend Analysis
6.1 Nanomedicine market: Application movement analysis
6.2 Clinical oncology
6.2.1 Global clinical oncology market, 2013 - 2024 (USD Billion)
6.3 Infectious diseases
6.3.1 Global infectious diseases market, 2013 - 2024 (USD Billion)
6.4 Clinical cardiology
6.4.1 Global clinical cardiology market, 2013 - 2024 (USD Billion)
6.5 Orthopedics
6.5.1 Global orthopaedics market, 2013 - 2024 (USD Billion)
6.6 Others applications
6.6.1 Global other applications market, 2013 - 2024 (USD Billion)
Chapter 7 Market Categorization 3: Regional Estimates & Trend Analysis, by Product & Application
7.1 Nanomedicine market share by region, 2015 & 2024
7.2 North America
7.2.1 North America nanomedicine market, 2013 - 2024 (USD Billion)
7.2.1.1 U.S. nanomedicine market, 2013 - 2024 (USD Billion)
7.2.2 Canada
7.2.2.1 Canada nanomedicine market, 2013 - 2024 (USD Billion)
7.3 Europe
7.3.1 Europe nanomedicine market, 2013 - 2024 (USD Billion)
7.3.2 Germany
7.3.2.1 Germany nanomedicine market, 2013 - 2024 (USD Billion)
7.3.3 UK.
7.3.3.1 UK nanomedicine market, 2013 - 2024 (USD Billion)
7.4 Asia Pacific
7.4.1 Asia Pacific nanomedicine market, 2013 - 2024 (USD Billion)
7.4.2 Japan
7.4.2.1 Japan nanomedicine market, 2013 - 2024 (USD Billion)
7.4.3 China
7.4.3.1 China nanomedicine market, 2013 - 2024 (USD Billion)
7.5 Latin America
7.5.1 Latin America nanomedicine market, 2013 - 2024 (USD Billion)
7.5.2 Brazil
7.5.2.1 Brazil nanomedicine market, 2013 - 2024 (USD Billion)
7.6 Middle East & Africa
7.6.1 Middle East & Africa nanomedicine market, 2013 - 2024 (USD Billion)
7.6.2 South Africa
7.6.2.1 South Africa nanomedicine market, 2013 - 2024 (USD Billion)
Chapter 8 Competitive Landscape
8.1 Strategy framework
8.2 Market participation categorization
8.3 Company profiles
8.3.1 Ablynx NV
8.3.1.1 Company Overview
8.3.1.2 Financial Performance
8.3.1.3 Product Benchmarking
8.3.1.4 Strategic Initiatives
8.3.2 Abraxis Bioscience Inc.
8.3.2.1 Company Overview
8.3.2.2 Financial Performance
8.3.2.3 Product Benchmarking
8.3.2.4 Strategic Initiatives
8.3.3 Amag Pharmaceuticals Inc.
8.3.3.1 Company Overview
8.3.3.2 Financial Performance
8.3.3.3 Product Benchmarking
8.3.3.4 Strategic Initiatives
8.3.4 Acusphere Inc.
8.3.4.1 Company Overview
8.3.4.2 Financial Performance
8.3.4.3 Product Benchmarking
8.3.4.4 Strategic Initiatives
8.3.5 Bind Therapeutics Inc.
8.3.5.1 Company Overview
8.3.5.2 Financial Performance
8.3.5.3 Product Benchmarking
8.3.5.4 Strategic Initiatives
8.3.6 Bioforce Nanosciences Inc
8.3.6.1 Company Overview
8.3.6.2 Financial Performance
8.3.6.3 Product Benchmarking
8.3.6.4 Strategic Initiatives
8.3.7 Combimatrix Corporation
8.3.7.1 Company Overview
8.3.7.2 Financial Performance
8.3.7.3 Product Benchmarking
8.3.7.4 Strategic Initiatives
8.3.8 Elan Drug Technologies
8.3.8.1 Company Overview
8.3.8.2 Financial Performance
8.3.8.3 Product Benchmarking
8.3.8.4 Strategic Initiatives
8.3.9 IGI Laboratories Inc.
8.3.9.1 Company Overview
8.3.9.2 Financial Performance
8.3.9.3 Product Benchmarking
8.3.9.4 Strategic Initiatives
8.3.10 Lumera Corp.
8.3.10.1 Company Overview
8.3.10.2 Financial Performance
8.3.10.3 Product Benchmarking
8.3.10.4 Strategic Initiatives
8.3.11 Magforce Naanotechnologies AG.
8.3.11.1 Company Overview
8.3.11.2 Financial Performance
8.3.11.3 Product Benchmarking
8.3.11.4 Strategic Initiatives
8.3.12 Magnamedics GmBh
8.3.12.1 Company Overview
8.3.12.2 Financial Performance
8.3.12.3 Product Benchmarking
8.3.12.4 Strategic Initiatives
8.3.13 Midatech Pharma PLC
8.3.13.1 Company Overview
8.3.13.2 Financial Performance
8.3.13.3 Product Benchmarking
8.3.13.4 Strategic Initiatives
8.3.14 Molecular Profiles
8.3.14.1 Company Overview
8.3.14.2 Financial Performance
8.3.14.3 Product Benchmarking
8.3.14.4 Strategic Initiatives
8.3.15 Nanocarrier Co.Ltd
8.3.15.1 Company Overview
8.3.15.2 Financial Performance
8.3.15.3 Product Benchmarking
8.3.15.4 Strategic Initiatives
8.3.16 Nanologix, Inc.
8.3.16.1 Company Overview
8.3.16.2 Financial Performance
8.3.16.3 Product Benchmarking
8.3.16.4 Strategic Initiatives
8.3.17 Nanoviricides Inc.
8.3.17.1 Company Overview
8.3.17.2 Financial Performance
8.3.17.3 Product Benchmarking
8.3.17.4 Strategic Initiatives

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report